M. A. N. Sendur Et Al. , "Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen," Medical Oncology , vol.31, no.9, pp.1-8, 2014
Sendur, M. A. N. Et Al. 2014. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Medical Oncology , vol.31, no.9 , 1-8.
Sendur, M. A. N., Ozdemir, N., Özatlı, T., Yazıcı, O., Aksoy, S., Ekinci, A. Ş., ... Yazılıtaş, D.(2014). Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Medical Oncology , vol.31, no.9, 1-8.
Sendur, Mehmet Et Al. "Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen," Medical Oncology , vol.31, no.9, 1-8, 2014
Sendur, Mehmet A. Et Al. "Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen." Medical Oncology , vol.31, no.9, pp.1-8, 2014
Sendur, M. A. N. Et Al. (2014) . "Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen." Medical Oncology , vol.31, no.9, pp.1-8.
@article{article, author={Mehmet Ali Nahit Sendur Et Al. }, title={Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen}, journal={Medical Oncology}, year=2014, pages={1-8} }